Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.PH)

AVEO.PH on Philadelphia Stock Exchange

3.77USD
18 Sep 2017
Change (% chg)

-- (--)
Prev Close
$3.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,665
52-wk High
$4.22
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma
Monday, 28 Aug 2017 06:17am EDT 

Aug 28 (Reuters) - Aveo Pharmaceuticals Inc :Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma.Aveo Oncology says EC has approved fotivdafor treatment of adult patients with advanced renal cell carcinoma in European Union plus Norway and Iceland.  Full Article

Aveo Pharmaceuticals Inc Q2 loss per share $0.30
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Aveo Pharmaceuticals Inc ::Aveo reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.30.Aveo pharmaceuticals inc - ‍believe that our $40.1 million in cash resources would allow us to fund our planned operations into q4 of 2018​.  Full Article

Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings
Tuesday, 27 Jun 2017 09:06am EDT 

June 27 (Reuters) - Aveo Pharmaceuticals Inc :Aveo Oncology announces $14m in aggregate gross proceeds from Hercules Credit Facility and at-the-market stock offerings.Aveo Pharmaceuticals Inc - intends to draw down an additional $5 million in funding from Hercules.Aveo Pharmaceuticals Inc - will defer commencement of principal payments on its aggregate loan balance by six months from July 1, 2017 until January 1, 2018..  Full Article

Aveo Oncology announces phase 1/2 tinivo trial
Thursday, 8 Jun 2017 07:00am EDT 

June 8 (Reuters) - Aveo Pharmaceuticals Inc ::Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2.Aveo Pharmaceuticals - "Registration strategy for single agent tivozanib reaches key inflection points, with European regulatory decision expected in near-term".Aveo - if registration strategy for single agent tivozanib reaches key inflection points, readout of us registration-directed tivo-3 study expected in Q1 of 2018.  Full Article

Aveo appoints Matthew Dallas chief financial officer
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - Aveo Pharmaceuticals Inc -:Aveo announces appointment of Matthew Dallas as chief financial officer.Aveo Pharmaceuticals Inc - Dallas succeeds Keith Ehrlich, whose retirement from company was previously announced.Aveo Pharmaceuticals Inc - appointment of Matthew Dallas as chief financial officer, effective June 1, 2017.  Full Article

Aveo announces submission of response to Tivozanib marketing authorization application day 180 list of outstanding issues
Thursday, 13 Apr 2017 08:00am EDT 

Aveo Pharmaceuticals Inc : Aveo announces submission of response to tivozanib marketing authorization application day 180 list of outstanding issues .Aveo Pharma - EUSA remains tentatively scheduled to provide oral explanation to EMA's committee for medicinal products for human use at May 2017 meeting.  Full Article

Aveo Pharmaceuticals says cash on hand would fund planned operations into Q2 2018
Wednesday, 5 Apr 2017 07:02am EDT 

Aveo Pharmaceuticals Inc :Aveo pharmaceuticals - "cash on hand would fund planned operations into 2Q 2018; beyond tivo-3 readout which is expected 1Q 2018" - sec filing.  Full Article

Aveo announces pricing of $15 mln public offering of common stock
Tuesday, 28 Mar 2017 09:09am EDT 

Aveo Pharmaceuticals Inc : Aveo announces pricing of $15.0 million public offering of common stock .Says public offering of 30.0 million common shares priced at $0.50per share.  Full Article

Aveo announces proposed offering of common stock
Tuesday, 28 Mar 2017 06:33am EDT 

Aveo Pharmaceuticals Inc : Aveo announces proposed offering of common stock .Aveo Pharmaceuticals- offering's proceeds to be used in development, pre-commercial expenses incurred for ongoing phase 3 clinical trial of tivozanib.  Full Article

Aveo Pharmaceuticals says doubts ability to continue as a going concern - SEC filing
Wednesday, 22 Mar 2017 04:35pm EDT 

Aveo Pharmaceuticals Inc : Aveo Pharmaceuticals says have identified conditions and events that raise substantial doubt about ability to continue as a going concern - SEC filing . Aveo Pharmaceuticals says "continue as a going concern, we must secure additional capital to provide us with additional liquidity" . Aveo Pharma - believe about $23.3 million in existing cash,cash equivalents, securities at Dec. 31, 2016, could allow to fund planned operations into Q4 2017 .Aveo Pharmaceuticals Inc says additional funds will be needed to extend planned operations into 2018.  Full Article

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma